Does Vitamin D₃ Supplementation Improve Exercise Tolerance of D₃ Deficient Chronic Obstructive Lung Disease Patients? - A Randomized Controlled Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

This study aimed to evaluate the effects of vitamin D₃ supplementation on exercise tolerance in D₃ deficient patients with COPD.

Why It Was Studied

Newer functional aspects of vitamin D₃ have been revealed in tissue and organs other than bones.

A double-blinded randomized controlled trial was carried out on 40 D₃ deficient [serum 25(OH)D <30 ng/ml], male, smoker (>4 pack years), stable COPD (post-bronchodilator FEV1/FVC <0.70) patients (age 40 to 80 years) and randomly allocated as study (n=20) and control (n=20).

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, men only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Their baseline exercise tolerance [6 minute walk distance (6MWD), dyspneic score, fatigue score] variables were measured.

What Was Measured

Topics PubMed links to this paper include Pulmonary Disease, Chronic Obstructive, Cholecalciferol, Exercise Tolerance, Dietary Supplements and Vitamin D Deficiency.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2026 (Mymensingh medical journal : MMJ), a journal based in Bangladesh.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.